- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
ASCO Declares CLL Regimens Cancer
In it's report, "Clinical Cancer Advances 2015: ASCO's Annual Report on Progress Against Cancer," published in the Journal of Clinical Oncology, 4 newly approved treatments for CLL were predicted to have a dramatic impact on patients with the disease.
Nearly 120,000 Americans are living with CLL, and approximately 90% are diagnosed over age 55. The newly approved treatments for CLL include:
The American Society of Clinical Oncology (ASCO) for the first time announced its cancer Advance of the Year: the transformation of treatment for the most common form of adult leukemia. Until now, many patients with chronic lymphocytic leukemia (CLL) have had few effective treatment options. Four newly approved therapies, however, are poised to dramatically improve the outlook for patients with the disease.
- Two immunotherapy drugs for previously untreated CLL, obinutuzumab and ofatumumab (in combination with standard chemotherapy)
- Two molecularly targeted drugs for treatment-resistant or relapsed CLL, ibrutinib and idelalisib
“These new therapies fill an enormous need for thousands of patients living with CLL,” said Gregory Masters, MD, FACP, FASCO, ASCO expert and co-executive editor of the report. “For many older patients, especially, these drugs essentially offer the first chance at effective treatment, since the side effects of earlier options were simply too toxic for many to handle.”
Link to the press release: http://bit.ly/1AIOZ5q
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Comparing Breast Cancer Treatment Outcomes Between Fee-for-Service and Medicare Advantage
April 4th 2025This study examined postdiagnosis breast cancer treatment outcomes for Medicare Advantage vs fee-for-service (FFS) Medicare in Ohio and found no significant differences overall but disparities for Black patients with FFS Medicare.
Read More
FDA Approves Cabozantinib for Advanced Pancreatic Neuroendocrine Tumors
March 26th 2025With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer Network guidelines, this approval reinforces cabozantinib’s role in improving outcomes for patients facing these challenging cancers.
Read More
